• WedgeGlobal media AOR: Mindshare (WPP) has held the AstraZeneca global media account since 2018 — one of WPP's flagship pharma wins, RENEWED multiple times since (most recently confirmed through 2024). This is a CORE WPP INCUMBENT relationship.
• WhyDirect oncology competitors in TW: Roche (Tagrisso vs. Tarceva/Tecentriq), MSD (Keytruda — dominant IO), BMS (Opdivo), Pfizer, Novartis, Lilly. CVRM competitors: Novartis (Entresto), BI/Lilly (Jardiance — direct Forxiga competitor), Bayer (Kerendia), Novo Nordisk (Ozempic). Respiratory: GSK (Trelegy, Nucala), Sanofi-Regeneron (Dupixent — direct Fasenra/Tezspire competitor). Rare disease: Sanofi, Takeda, Pfizer.

1. W1Global media AOR: Mindshare (WPP) has held the AstraZeneca global media account since 2018 — one of WPP's flagship pharma wins, RENEWED multiple times since (most recently confirmed through 2024). This is a CORE WPP INCUMBENT relationship.
2. W2Global creative: Mixed — AstraZeneca uses multiple creative agencies including VML (WPP), McCann Health (IPG), Saatchi & Saatchi Wellness for different therapy areas. No single global creative AOR.
3. W3AZ is one of the fastest-growing pharma majors — increasing marketing budget overall (US$80B 2030 target announced 2024)
4. W4Enhertu (with Daiichi Sankyo) is a category-creating ADC therapy — strong Taiwan launch wave
5. W5COVID-19 vaccine (Vaxzevria) global production wind-down complete; Evusheld withdrawn — V&I marketing footprint shrunk significantly post-2023
6. W6Alexion rare-disease portfolio integration (acquired 2021) creates rare-disease patient-advocacy campaign expansion

• Direct oncology competitors in TW: Roche (Tagrisso vs. Tarceva/Tecentriq), MSD (Keytruda — dominant IO), BMS (Opdivo), Pfizer, Novartis, Lilly. CVRM competitors: Novartis (Entresto), BI/Lilly (Jardiance — direct Forxiga competitor), Bayer (Kerendia), Novo Nordisk (Ozempic). Respiratory: GSK (Trelegy, Nucala), Sanofi-Regeneron (Dupixent — direct Fasenra/Tezspire competitor). Rare disease: Sanofi, Takeda, Pfizer.
• HIGH (defensive). WPP MEDIA TAIWAN HOLDS THE INCUMBENT GLOBAL MEDIA AOR for AstraZeneca via Mindshare since 2018 — this is one of WPP's most strategic pharma media relationships globally. Renewed multiple times. AZ Taiwan media-buying cascades through Mindshare/GroupM (now WPP Media) Asia network. THIS IS A DEFEND-THE-INCUMBENT account for WPP Taiwan — Jimmy Kuo's team. Plus: VML Health (WPP) has multiple AZ creative project wins globally. Pitch posture: defensive on media (relationship-protection, scope-expansion into oncology and CVRM new launches), offensive on creative carve-outs (no single global creative AOR means therapy-area pitches are feasible).
• Tagrisso NHI reimbursement renewals — flagship oncology revenue driver
• Enhertu Taiwan NHI access / breast cancer + lung HER2 expansion
• Forxiga competitive defense vs Jardiance
• AstraZeneca Taiwan Country President / GM changes (vendor review trigger)
• Global AZ quarterly earnings — innovative-medicines marketing spend disclosures
• Patient organization partnership announcements (TLCS, TADA, TRA)

• Country President / GM AstraZeneca Taiwan — incumbent unverifiedCountry President AZ Taiwan

  since

  Position rotates ~3-4 years. LinkedIn/press diligence required to confirm current incumbent.

  Source ↗
• BU Heads — Oncology (largest), CVRM, R&I, V&I, Rare DiseaseBusiness Unit Director — AZ Taiwan

  since

  Therapy-area BU directors hold P&L for brand spend. Oncology BU is the single largest budget pool. Highest priority for agency relationships: Oncology head and CVRM head.

  Source ↗

AstraZeneca Taiwan is a top-5 MNC pharma in Taiwan, founded 1999 via Astra-Zeneca merger; AstraZeneca Taiwan (台灣阿斯特捷利康) headquartered in Taipei. Globally AstraZeneca surpassed US$50B revenue 2024 and is on track for US$80B by 2030 — fastest-growing big pharma. Taiwan portfolio is HEAVILY oncology-weighted: Tagrisso is dominant EGFR-mutated NSCLC therapy in TW (lung cancer = #1 cancer killer in Taiwan, EGFR mutation prevalence ~50%+ in TW NSCLC — geographically the most important market outside China/Japan for Tagrisso). Imfinzi, Enhertu, Lynparza all major. Forxiga is major CVRM driver. Taiwan Rx DTC restricted (藥事法); consumer-facing spend is (a) corporate brand (CSR/health innovation), (b) unbranded disease-awareness (lung cancer screening, heart failure, severe asthma, lupus), (c) patient association work (Taiwan Lung Cancer Society, TW Diabetes Assoc, TW Rheumatology), (d) HCP digital + medical congresses. COVID-19 vaccine era (Vaxzevria) created brief consumer-facing footprint 2021-2022; now wound down. Estimated NT$250-450M ad spend, mid-tier.

No campaigns surfaced in research.

No decision-makers identified.

AstraZeneca Taiwan reports into AZ Asia Area (Shanghai/Singapore hubs). Country President / GM rotates ~3-4 years. Commercial structure split by therapy area: Oncology BU (largest), CVRM BU, Respiratory & Immunology BU, V&I (vaccines), Rare Disease (Alexion legacy). Each BU has its own brand team and agency partners. Global creative + media operations report to AstraZeneca Global Commercial Operations (Cambridge UK + Wilmington DE).